Zhenzhen Liang1, Xin Liu1, Qian Zhang1, Chunpeng Wang2, Yinlong Zhao3. 1. Dept. Epidemiology and Statistics, School of Public Health, Jilin University, Changchun, Jilin, China. 2. School of Mathematics and Statistics, Northeast Normal University, Changchun, Jilin, China. Electronic address: liuxin2015722010@163.com. 3. Dept. Nuclear Medicine, 2nd Hospital, Jilin University, Changchun, China. Electronic address: 1370118262@qq.com.
Abstract
BACKGROUND: It has been reported that microRNAs might serve as biomarkers for cholangiocarcinoma (CCA) detection, but their diagnostic accuracy are unclear and controversial. AIM: To evaluate the diagnostic accuracy of microRNAs for CCA. MATERIALS AND METHODS: PubMed, Embase, Web of Science and Cochrane Library were systematically searched to identify relevant articles by using the key words "cholangiocarcinoma" and "microRNA". The methodological quality of each study was assessed by QUADAS-2. According to the inclusive and exclusive criteria, 11 articles were identified and analyzed by Meta-disc software v.1.4 and STATA 12.0 software package. RESULTS: 11 articles with 430 CCA patients and 406 controls were identified. The results showed that the pooled sensitivity was 0.756 (95% CI: 0.693-0.810), specificity was 0.914 (95% CI: 0.861-0.947), positive likelihood ratio was 8.747 (95% CI: 5.320-14.381), negative likelihood ratio was 0.267 (95% CI: 0.208-0.341) and diagnostic odds ratio was 32.791 (95% CI: 17.327, 62.060). In addition, the area under the summary ROC cure (AUC) was 0.90 (95% CI: 0.87-0.93). CONCLUSION: MicroRNAs have great potential as biomarkers for the diagnosis of CCA patients. However, the clinical application of microRNA assays for CCA diagnosis still needs further validation by more prospective studies.
BACKGROUND: It has been reported that microRNAs might serve as biomarkers for cholangiocarcinoma (CCA) detection, but their diagnostic accuracy are unclear and controversial. AIM: To evaluate the diagnostic accuracy of microRNAs for CCA. MATERIALS AND METHODS: PubMed, Embase, Web of Science and Cochrane Library were systematically searched to identify relevant articles by using the key words "cholangiocarcinoma" and "microRNA". The methodological quality of each study was assessed by QUADAS-2. According to the inclusive and exclusive criteria, 11 articles were identified and analyzed by Meta-disc software v.1.4 and STATA 12.0 software package. RESULTS: 11 articles with 430 CCA patients and 406 controls were identified. The results showed that the pooled sensitivity was 0.756 (95% CI: 0.693-0.810), specificity was 0.914 (95% CI: 0.861-0.947), positive likelihood ratio was 8.747 (95% CI: 5.320-14.381), negative likelihood ratio was 0.267 (95% CI: 0.208-0.341) and diagnostic odds ratio was 32.791 (95% CI: 17.327, 62.060). In addition, the area under the summary ROC cure (AUC) was 0.90 (95% CI: 0.87-0.93). CONCLUSION: MicroRNAs have great potential as biomarkers for the diagnosis of CCA patients. However, the clinical application of microRNA assays for CCA diagnosis still needs further validation by more prospective studies.
Authors: Jesus M Banales; Jose J G Marin; Angela Lamarca; Pedro M Rodrigues; Shahid A Khan; Lewis R Roberts; Vincenzo Cardinale; Guido Carpino; Jesper B Andersen; Chiara Braconi; Diego F Calvisi; Maria J Perugorria; Luca Fabris; Luke Boulter; Rocio I R Macias; Eugenio Gaudio; Domenico Alvaro; Sergio A Gradilone; Mario Strazzabosco; Marco Marzioni; Cédric Coulouarn; Laura Fouassier; Chiara Raggi; Pietro Invernizzi; Joachim C Mertens; Anja Moncsek; Sumera Rizvi; Julie Heimbach; Bas Groot Koerkamp; Jordi Bruix; Alejandro Forner; John Bridgewater; Juan W Valle; Gregory J Gores Journal: Nat Rev Gastroenterol Hepatol Date: 2020-06-30 Impact factor: 46.802